- 作者：Vincenzo La Mura ; Amalia De Renzo ; Fabiana Perna ; Diego D’ ; Agostino ; Mario Masarone ; Marco Romano ; Savino Bruno ; Roberto Torella ; Marcello Persico
- 关键词：Non-Hodgkin’ ; s lymphoma ; Hepatitis C antiviral therapy
- 刊名：Journal of Hepatology
- 出版年：2008
- 出版时间：October 2008
- 年：2008
- 卷：49
- 期：4
- 页码：557-563
- 全文大小：274 K
lass=""h4"">Background/Aims
Prevalence of HCV infection in non-Hodgkin’s lymphoma is high. The impact of antiviral therapy on the natural history of this subgroup of lymphomas after a successful chemotherapy regimen is still an argument of debate.lass=""h4"">Methods
We retrospectively examined 343 chemotherapy-treated patients referred to our centre for five consecutive years. Clinical and histological characteristics, disease free-survival (DFS) and overall-survival (OS) were compared in HCV-positive (69/343) and HCV-negative (274/343) patients. Twenty-five HCV-positive patients received antiviral treatment following chemotherapy discontinuation. Uni- and multivariate analyses were performed.
lass=""h4"">Results
20 % of lymphomas were HCV-positive. Indolent histology was prevalent in the HCV-positive group (p < 0.05); no significant differences in OS or DFS were found between the two groups; in HCV-positive subjects, antiviral therapy, was associated with a longer DFS (p < 0.05); none of the HCV-positive subjects who achieved a virological response experienced any lymphoma relapse; 29 % of non responders did; at multivariate analysis, the independent factors related to a better clinical outcome were: indolent histology at the onset of lymphoma and antiviral therapy.
lass=""h4"">Conclusions
Antiviral treatment in HCV-positive non-Hodgkin’s lymphoma may be an important strategy to reinforce the results of a successful chemotherapy regimen; further studies are needed to validate this combined approach.